We are pleased to announce the new dates and location for the Trans-Pacific Health Sciences Dialogue 2015:
October 14-15, 2015
The Joseph B. Martin Conference Center at Harvard Medical School, Boston, MA
More information coming soon.
Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!
About the Conference
The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.
Industry News from BioCentury
- NICE backs Harvoni for some HCV patientsThe U.K.'s NICE published draft guidance recommending Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) as a cost-effective treatment for certain subpopulations of patients with HCV genotypes 1 and 4 at a list price of L38,980 ($60,017) for a 12-week course. Comments are due March 23.
NICE recommended an 8-week course of Harvoni for treatment-naive, non-cirrhotic patients with HCV genotype 1. The committee recommended a 12-week course for treatment-naive genotype 1 and 4 patients with cirrhosis and for previously-treated, non-cirrhotic patients with genotypes 1 or 4. The draft guidance did not recommend Harvoni for previously-treated patients with cirrhosis, nor to treat genotype 3.
The European Commission approved Harvoni last November to treat chronic HCV genotype 1, 3 and 4 infection (see BioCentury Extra, Nov. 18, 2014).
Harvoni's U.K. list price is 36% lower than its $94,500 WAC in the U.S. FDA approved the drug in October (see BioCentury Extra, Oct. 10, 2014).
Harvoni is a once-daily fixed-dose combination of 90 mg of the HCV NS5A protein inhibitor ledipasvir plus 400 mg of Gilead's nucleotide analog HCV NS5B polymerase inhibitor Sovaldi sofosbuvir.
Industry News from PharmAsia
- Daewoong Inks Autotelic Deal To Help International ExpansionAfter a fairly smooth launch for its combination drug Olostar in South Korea last year, Daewoong is now taking the product into global markets as part of its international expansion strategy.<img src="//feeds.feedburner.com/~r/_PharmAsiaNews/~4/L51Y1uDV13g" height="1" width="1" alt="" />